Immunotoxins containing Pseudomonas exotoxin A: A short history

Cancer Immunology, Immunotherapy

Volumn 52, Issue 5, 2003, Pages 338-341

  Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; IMMUNOTOXIN LMB2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BL22; MONOCLONAL ANTIBODY ERB38; MONOCLONAL ANTIBODY LMB1; MONOCLONAL ANTIBODY LMB7; MONOCLONAL ANTIBODY LMB9; MONOCLONAL ANTIBODY SS1P; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

CANCER REGRESSION; CONFERENCE PAPER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TUMOR REGRESSION;

EID: 0038290547     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0353-8     Document Type: Conference Paper

References (22)

1. Willingham MC, Pastan I (1980) The receptosome: an intermediate organelle or receptor-mediated endocytosis in cultured fibroblasts. Cell 21:67
2. FitzGerald DJP, Padmanabhan R, Pastan IH, Willingham MC (1983) Adenovirus-induced release of epidermal growth factor and Pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell 32:607
3. FitzGerald DJP, Waldmann TA, Willingham MC, Pastan I (1984) PE-anti-TAC: a cell-specific immunotoxin active against cells expressing the human T-cell growth factor receptor. J Clin Invest 74:966
4. Allured VS, Collier RJ, Carroll SF, McKay DB (1986) Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Ångstrom resolution. Proc Natl Acad Sci USA 83:1320
5. Hwang J, FitzGerald DJP, Adhya S, Pastan I (1987) Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48:129
6. Siegall CB, Ogata M, Pastan I, FitzGerald DJ (1991) Analysis of sequences in domain II of Pseudomonas exotoxin A which mediate translocation. Biochemistry 30:7154
7. Pastan I, Lovelace ET, Gallo MG, Rutherford AV, Magnani JL, Willingham MC (1991) Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res 51:3781
8. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I (1996) Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nature Med 2:350
9. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I (1989) A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339:394
10. Brinkmann U, Buchner J, Pastan I (1992) Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections. Proc Natl Acad Sci USA 89:3075
11. Brinkmann U, Reiter Y, Jung S-H, Lee B, Pastan I (1993) A recombinant immunotoxin containing a disulfide-stabilized Fv fragment (dsFv). Proc Natl Acad Sci USA 90:7538
12. Mansfield E, Amlot P, Pastan I, FitzGerald D (1997) Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 80:2020
13. Kreitman RJ, Wang Q-C, FitzGerald DJP, Pastan I (1999) Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-38 at doses tolerated by cynomolgus monkeys. Int J Cancer 81:148
14. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241
15. Benhar I, Reiter Y, Pai LH, Pastan I (1995) Administration of disulfide-stabilized Fv-immunotoxins B1(dsFV)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int J Cancer 62:351
16. Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers. Proc Natl Acad Sci USA 93:136
17. Chowdhury P, Viner JL, Beers R, Pastan I (1998) Isolation of a high affinity stable single chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA 95:669
18. Chowdhury PS, Pastan I (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro. Nature Biotechnol 17:568
19. Pai-Scherf L, Villa J, Pearson D, Watson T, Liu E, Willingham MC, Pastan I (1999) Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 5:2311
20. Jain RK (1999) Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1:241
21. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I (2000) Site-specific chemical modification of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 97:8548
22. Wang QC, Pai LH, Debinski W, FitzGerald DJ, Pastan I (1993) Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. Cancer Res 53:4588